- Veterans Agency to Offer New Depression Drug, Despite Cost and Safety Concerns The New York Times
- VA declines broad coverage for new J&J depression drug touted by Trump STAT
- Cost-effectiveness watchdogs skewer Novartis’ MS drug Mayzent and J&J’s depression spray Spravato FiercePharma
- J&J’s Spravato for depression ‘should be much cheaper’ pharmaphorum
- View full coverage on Google News
Brought to you by Google News. Read the rest of the article here.